Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.46M 9.95M 9.25M 8.5M 16.07M 16.32M 109M 42.85M 544M 43.04M 42.09M 1.82B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.25M 10.63M 9.89M 9.09M 17.17M 17.45M 116M 45.81M 582M 46M 44.99M 1.95B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
44.12%
Yield 2024 *
-
Yield 2025 -
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-19 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
26/12/24 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
11/12/24 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
1 day+2.30%
1 week-4.81%
1 month-11.44%
3 months+8.93%
6 months-0.93%
Current year-23.91%
1 week 57.5
Extreme 57.5
65.49
1 month 57.5
Extreme 57.5
79.69
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
164.02
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 23/01/2002
Chief Executive Officer - 01/06/2026
President 57 23/08/2023
Director TitleAgeSince
Director/Board Member 53 23/11/2022
Director/Board Member 62 10/09/2010
Director/Board Member - 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.30%-4.81%-60.39%-29.09% 18.82M
-0.53%+2.54%+16.63%+74.09% 50.03B
-1.81%-0.49%+51.99%+112.44% 36.6B
+0.46%+4.44%-5.24%+25.38% 12.47B
+1.05%+1.63%+16.19%+78.22% 11.77B
-1.33%-0.76%+30.08%+131.70% 9.04B
-2.99%-2.09%+41.02%-8.36% 7.03B
+0.51%+1.46%+12.17%+32.88% 6.79B
-.--%+0.14% - - 6.79B
+1.99%+1.91%+4.68%+183.54% 6.6B
Average -0.04%+0.42%+11.90%+66.76% 14.71B
Weighted average by Cap. -0.62%+1.27%+25.17%+82.83%

Financials

2024 2025
Net sales 795M 8.33M 7.23M 6.73M 6.18M 11.68M 11.87M 79.24M 31.16M 396M 31.29M 30.61M 1.33B 826M 8.65M 7.51M 6.99M 6.42M 12.13M 12.33M 82.3M 32.36M 411M 32.5M 31.79M 1.38B
Net income -196M -2.05M -1.78M -1.66M -1.52M -2.88M -2.93M -19.53M -7.68M -97.58M -7.71M -7.54M -327M -99.67M -1.04M -907K -844K -775K -1.46M -1.49M -9.94M -3.91M -49.64M -3.92M -3.84M -166M
Net Debt 55.16M 578K 502K 467K 429K 811K 824K 5.5M 2.16M 27.47M 2.17M 2.12M 91.99M 75.39M 790K 686K 638K 586K 1.11M 1.13M 7.52M 2.96M 37.55M 2.97M 2.9M 126M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
31/07/26 ₹60.98 +2.30% 11,618
30/07/26 ₹59.61 -0.45% 21,976
29/07/26 ₹59.88 -4.57% 55,756
28/07/26 ₹62.75 -1.88% 7,486
27/07/26 ₹63.95 -0.17% 8,324
  1. Stock Market
  2. Stocks
  3. BROOKS Stock